Literature DB >> 10901289

The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy?

G Maury1.   

Abstract

This review is primarily intended for synthetic bio-organic chemists and enzymologists who are interested in new strategies in the design of virus inhibitors. It is an attempt to assess the importance of the enzymatic properties of L-nucleosides and their analogues, particularly those that are active against viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), herpes simplex virus (HSV), etc. Only data obtained with purified enzymes have been considered and discussed. The examined enzymes include nucleoside- or nucleotide-phosphorylating enzymes, catabolic enzymes, viral target enzymes and cellular polymerases. The enantioselectivities of these enzymes were determined from existing data and are significant only when a sufficient number of enantiomeric pairs of substrates could be examined. The reported data emphasize the weak enantioselectivities of cellular or viral nucleoside kinases and some viral DNA polymerases. Thus, cellular deoxycytidine kinase has a considerably relaxed enantioselectivity with respect to a large number of nucleosides or their analogues, and it occupies a strategic position in the intracellular activation of the compounds. Similarly, HIV-1 reverse transcriptase often has a relatively weak enantioselectivity and can be inhibited by the 5-triphosphates of a large series of L-nucleosides and analogues. In contrast, degradation enzymes, such as adenosine or cytidine deaminases, generally demonstrate strict enantioselectivities favouring D-enantiomers and are used by chemists in asymmetric syntheses. The weak enantioselectivities of some enzymes involved in nucleoside metabolism are more or less pronounced, and one enantiomer or the other is favoured depending on the substrate. This suggests that the low enantioselectivity is fortuitous and does not result from evolutionary pressure, since these enzymes do not create or modify asymmetric centres in substrates. The combined enantioselectivities of the enzymes examined in this review strongly suggest that the field of L-nucleosides and their analogues should be systematically explored in the search for new virus inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901289     DOI: 10.1177/095632020001100301

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  12 in total

1.  Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine.

Authors:  Justin G Julander; Richard A Bowen; Jagadeeshwar R Rao; Craig Day; Kristiina Shafer; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2008-08-15       Impact factor: 5.970

2.  Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.

Authors:  Hong-Wang Zhang; Mervi Detorio; Brian D Herman; Sarah Solomon; Leda Bassit; James H Nettles; Aleksandr Obikhod; Si-Jia Tao; John W Mellors; Nicolas Sluis-Cremer; Steven J Coats; Raymond F Schinazi
Journal:  Eur J Med Chem       Date:  2011-05-30       Impact factor: 6.514

3.  QSPR modeling of optical rotation of amino acids using specific quantum chemical descriptors.

Authors:  Karina Kapusta; Natalia Sizochenko; Sedat Karabulut; Sergiy Okovytyy; Eugene Voronkov; Jerzy Leszczynski
Journal:  J Mol Model       Date:  2018-02-17       Impact factor: 1.810

4.  Novel PET probes specific for deoxycytidine kinase.

Authors:  Chengyi J Shu; Dean O Campbell; Jason T Lee; Andrew Q Tran; Jordan C Wengrod; Owen N Witte; Michael E Phelps; Nagichettiar Satyamurthy; Johannes Czernin; Caius G Radu
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

5.  Sulfanilamide Modified Magnetic Nanoparticles for Purification of Carbonic Anhydrase from Bovine Blood.

Authors:  Safinur Yıldırım Çelik; Kübra Solak; Ahmet Mavi
Journal:  Appl Biochem Biotechnol       Date:  2022-06-01       Impact factor: 2.926

6.  Inhibition of guanosine monophosphate synthetase by the substrate enantiomer L-XMP.

Authors:  Nicholas B Struntz; Tianshun Hu; Brian R White; Margaret E Olson; Daniel A Harki
Journal:  Chembiochem       Date:  2012-10-23       Impact factor: 3.164

7.  Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2007-05-27       Impact factor: 7.446

8.  Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.

Authors:  Johannes Schwarzenberg; Caius G Radu; Matthias Benz; Barbara Fueger; Andrew Q Tran; Michael E Phelps; Owen N Witte; Nagichettiar Satyamurthy; Johannes Czernin; Christiaan Schiepers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-03       Impact factor: 9.236

9.  Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Stephen K Burley; Arnon Lavie
Journal:  Nucleic Acids Res       Date:  2006-12-07       Impact factor: 16.971

10.  Enantioselectivity of human AMP, dTMP and UMP-CMP kinases.

Authors:  Julie A C Alexandre; Béatrice Roy; Dimitri Topalis; Sylvie Pochet; Christian Périgaud; Dominique Deville-Bonne
Journal:  Nucleic Acids Res       Date:  2007-07-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.